25 August 2018 in News

Patient recruitment finalised in Stayble´s clinical phase Ib trial

Stayble is happy to announce that the last patient in the ongoing clinical phase Ib trial was treated with STA363 on August 25. Preliminary results will be available before the end of the year and the final report in Q1 2019. Stayble is now focusing fully on the next step of continued financing and planning of a Proof of Concept clinical phase II trial.

For more details, please contact Andreas Gerward, CEO